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INTRODUCTION 
The combining of two drugs may cause an interaction which either 
enhances or diminishes the beneficial or adverse effects of either 
agent. An interaction between two antiarrhythmic drugs, disopyramide 
1-4 
and phenytoin, has recently been reported. In this interaction, 
phenytoin appears to decrease the therapeutic effect while enhancing 
the toxic effects of disopyramide. Disopyramide slows the conduction 
velocity, prolongs the effective refractory period of the action 
potential and decreases automaticity of normal and diseased fibers in 
the heart. These properties enable disopyramide to treat both 
atrial and ventricular arrhythmias. Phenytoin, although not approved 
by the FDA as an antiarrhythmic drug, is often combined with other 
agents such as disopyramide in the treatment of ventricular 
arrhythmias. 
Effective serum concentrations of disopyramide range from 2 to 4 
mcg/ml."''^  Approximately 85 percent of oral disopyramide is 
6 8 6 absorbed. ' The volume of distribution is 0.8 L/kg with up to 80 
percent being protein bound primarily to alphas-acid glycoprotein.'7 
Wide interpatient variability of disopyramide serum protein binding 
has been reported, ranging from 30 to 80 percent.^'^'^ Serum protein 
binding of disopyramide decreases with increasing serum concentra-
tions; at therapeutic serum concentrations 18 to 25 percent of the 
drug may be free.^ Total disopyramide concentrations exhibit non-
linear disposition kinetics, whereas the free fraction of disopyramide 
exhibits linear disposition kinetics.^ 
In healthy volunteers, the half-life of disopyramide ranges from 
4 to 10 hours.^ Fifty percent of disopyramide is excreted 
unchanged in the urine while an additional 25 percent is metabolized 
by microsomal enzyme systems to mono-N-dealkyl disopyramide (MND).^ 
MND is four times less potent than disopyramide as an antiarrhythmic 
6 12 
agent ' yet has 20 times the anticholinergic activity of disopyra-
mide when measured in vitro utilizing the isolated guinea pig prepara-
13 
tion. MND is excreted in the urine and has a half-life of about 12 
10 
hours. Phenytoin induces the hepatic microsomal cytochrome p-450 
14 
oxidation system which is responsible for N-dealkylation. Because 
disopyramide is partially metabolized by this system, and because its 
effective serum concentration range is narrow, enzyme induction by 
% 
phenytoin could result in subtherapeutic serum concentrations of 
disopyramide. 
1-4 
A limited number of studies suggest that phenytoin affects 
1 2 
disopyramide serum concentrations. Aitio et al ' reported the effect 
of enzyme induction on the metabolism of disopyramide in two studies. 
In one study,* three patients receiving both disopyramide and pheny-
toin exhibited low disopyramide serum concentrations and high concentra-
2 
tions of disopyramide' s metabolite, MND. In the other study, in 
which a single dose of disopyramide was given to two healthy volun-
teers before and after one week of phenytoin administration, phenytoin 
3 
increased the metabolism of disopyramide. Kessler et al reported two 
cases in which a disopyramide and phenytoin interaction occurred. 
Both patients had decreased concentrations of disopyramide after 
4 
treatment with phenytoin. Matos et al published an abstract of a study with eight pa ie ts on concurrent disopyramide nd phenytoin
therapy. The mean serum concentration of disopyramide more than 
halved with the addition of phenytoin therapy. 
Thus, an interaction between disopyramide and phenytoin has been 
documented in 15 individuals. The current study was a prospective 
controlled evaluation of the effect of phenytoin on the disposition of 
disopyramide in normal volunteers. The objective was to determine if 
an interaction existed. 
METHODS 
Study Design 
This study, conducted in August 1983, was a prospective pharmaco-
kinetic study of disopyramide in normal volunteers. Each subject 
served as his own control. Permission to conduct the study was 
granted by the Institutional Review Board of the University of Utah. 
Each subject gave written informed consent prior to the study. 
(Appendix A) 
Patient Selection 
Ten healthy volunteers, with a median age of 25.5 years (range 
23-36) and a median body weight of 80 kilograms (range 71-93) partici-
pated in the study. A physical examination, medication history and 
laboratory screening including complete blood count with differential, 
SMA-20, urinalysis, electrocardiogram and chest x-ray was obtained on 
each subject. 
Subjects were admitted to the study if they met the following 
criteria for inclusion: normal physical examination, normal renal and 
hepatic function, no history of cigarette smoking within the past six 
4 
months and no chronic drug therapy. The subjects were asked to 
refrain from drinking alcoholic beverages during the study. 
Prospective participants were excluded from the study if they received 
medications known or suspected to interact with disopyramide or 
phenytoin during the month prior to or throughout the study or if they 
had a history of hypersensitivity to either disopyramide or phenytoin. 
Procedures 
On day 1, following an overnight fast, all subjects received a 
single oral dose of disopyramide (Norpace®) 300 mg and began a 24 hour 
urine collection. The subjects swallowed the disopyramide with 120 ml 
of water and, one hour after the dose, ate a standardized breakfast. 
Blood samples were collected at 0, 0.25, 0.50, 0.75, 1, 2, 3, 6, 8, 12 
and 24 hours following the administration of disopyramide. On day 2, 
the subjects began a 13 day course of oral phenytoin (Dilantin®), 300 
mg daily as a single dose. On day 14, all subjects again received a 
single oral dose of disopyramide and began a 24 hour urine collection. 
Blood samples were collected in the same fashion as after the first 
dose. The concentration of phenytoin in the blood was measured on day 
14. Vital signs were recorded prior to and at 6, 12 and 24 hours 
after the dose of disopyramide was given. The subjects were inter-
viewed every three days by the primary investigator to assess adverse 
effects from disopyramide and phenytoin administration (Appendix B) as 
well as compliance with daily phenytoin therapy. 
Instrumentation and Data Collection 
Blood samples (5 ml) were collected in Vacutainers® (Vacutainer 
Systems, Rutherford, NJ). Disopyramide blood samples were centrifuged 
5 
within 30 minutes of collection. The serum was stored at -20°C until 
the end of the study period and then assayed at Searle Laboratories, 
Skokie, IL. Of 219 samples collected, 215 were assayed by the Emit® 
system (Svva Inc., Palo Alto, CA) and 4 by gas chromatography. The 
Emit® system^ quantitates total disopyramide serum concentration 
(unbound plus protein bound) with a coefficient of variation of less 
than ten percent. The assay has been specifically designed for 
optimum sensitivity within the range of 0.5 mcg/ml to 8.0 mcg/ml of 
disopyramide. The coefficient of variation for gas chromatography 
analysis is also less than 
ten percent but the sensitivity of the 
assay is limited to 0.25 mcg/ml.^ Phenytoin concentrations were 
assayed at the University of Utah Hospital laboratory by Abbott's TDX® 
fluorescent polarization system (North Chicago, IL). The coefficient 
of variation for this assay at University Hospital is less than 12 
percent for all samples tested. 
Pharmacokinetic Calculations and Statistical Analysis 
The following kinetic parameters were calculated for disopyramide 
before and after phenytoin administration. The maximum plasma concen-
tration (Cp max) and the time of its occurrence were obtained from 
measured values. The area under the plasma concentration-time curve 
up to the last sampling point was calculated by the linear trapezoidal 
CO 
method, and the area to infinity [AUC]q was calculated by adding to 
this value the area obtained by dividing the last plasma concentration 
by the elimination rate constant. The elimination rate constant (kel) 
was determined by linear regression analysis for the terminal plasma 
concentrations plotted on a logarithmic axis which declined in a 
linear manner. Half-life was calculated according to the equation 
6 
th = 0.693/k^, where t% is the half-life and k ^ is the elimination 
rate constant. Apparent volume of distribution was calculated using 
the equation Vd = (Dose x f)/(k^ x [AUC]^) where Vd is the apparent 
volume of distribution, k . is the elimination rate constant, f is the 
el 
CO 
fraction of the dose absorbed and [AUC]q is the area under the plasma 
concentration-time curve extrapolated to infinity. Clearance was 
calculated using the equation CI = Vd*x where CI is clearance, Vd 
is the apparent volume of distribution and k ^ is the elimination rate 
* 
constant. 
Statistical analysis of each of these pharmacokinetic parameters 
was performed by the Student's paired t-test. For all statistical 
testing, p less than 0.05 was considered the minimal level of accept-
able significance. 
RESULTS 
Individual serum concentrations of disopyramide before and after 
phenytoin administration are shown in Table 1. Individual serum 
concentrations of phenytoin are shown in Table 2. A graph of mean 
concentrations versus time data for both pre- and post-phenytoin/ 
disopyramide serum concentrations is presented in Figure 1. The 
results of the calculations of disopyramide serum concentrations 
before and after phenytoin are included in Tables 3 through 9. The 
mean area under the plasma concentration time curve of disopyramide 
before and after phenytoin administration was 39.1 and 18.5 meg 
-hr/ml, respectively. The mean half-life of disopyramide before and 
after phenytoin administration was 8.2 and 4.0 hr, respectively. The 
mean apparent volume of distribution of disopyramide was 1 L/kg before 
and after phenytoin administration. The mean clearance of 
7 
disopyramide before and after phenytoin administration was 111 and 238 
ml/min, respectively. The mean elimination rate constant of disopyra-
mide before and after phenytoin administration was 0.066 and 0.174 
hr *, respectively. The mean maximum plasma concentration of disopyra-
mide before and after phenytoin administration was 3.0 and 2.9 mcg/ml, 
respectively. The mean time to maximum plasma concentration of 
disopyramide before and after phenytoin administration was 1.8 and 1.1 
hr, respectively. 
Phenytoin administration was associated with a statistically 
significant decrease in the mean area under the plasma concentration-
time curve, half-life and the time to maximum plasma concentration of 
disopyramide; whereas evaluation of the elimination rate constant and 
4 
clearance demonstrated a statistically significant increase. 
Serum concentrations of less than 0.5 mcg/ml of disopyramide were 
reported by Searle Laboratories, although the lower sensitivity of the 
Emit® assay is 0.5 mcg/ml. We chose not to include these data points 
in our calculations presented in Tables 3 through 9. We did, however, 
calculate the mean area under the plasma concentration-time curve and 
half-life of disopyramide before and after phenytoin administration 
including data points less than 0.5 mcg/ml and compared these results 
with those obtained excluding these points. There was no difference 
in the results as shown in Table 10. 
Each of the 10 subjects reported 100 percent compliance and no 
adverse effects associated with phenytoin therapy, although 4 of the 
subjects demonstrated nystagmus on physical examination. Dry mouth 
and drowsiness were the most common adverse effects reported after the 
initial dose of disopyramide. After two weeks of phenytoin 
8 
therapy the adverse effects associated with the disopyramide dose 
increased both in number and severity. These adverse effects were 
anticholinergic and included dry mouth (9 of 10 subjects), dry eyes (4 
subjects), blurred vision (3 subjects), constipation (1 subject), 
stomach cramps (1 subject) and urinary hesitancy (1 subject). 
DISCUSSION 
Previous studies on the interaction between disopyramide and 
phenytoin show that phenytoin decreases serum disopyramide concentra-
1-4 1 tions. Aitio et al noted an increase in the metabolism and a 
decrease in the efficacy of disopyramide in patients who were concur-
rently receiving agents which can induce hepatic enzymes. Three 
patients receiving disopyramide and•phenytoin demonstrated a decrease 
in disopyramide serum concentrations and an increase in the serum 
concentrations of the major metabolite of disopyramide, MND. Aitio et 
2 
al supported these initial findings with two additional volunteers 
who demonstrated a decrease in serum disopyramide area under the 
plasma concentration-time curve, an increase in MND serum concentra-
tions and an increase in the MND/disopyramide ratio in a 24 hour urine 
collection after concomitant phenytoin administration. This study 
demonstrated a statistically significant interaction between disopyra-
mide and phenytoin due to an increase in the metabolism of disopyra-
mide . 
4 3 
The reports of Matos et al and Kessler et al provide ten addi-
tional cases of patients on concurrent disopyramide and phenytoin 
4 
therapy. Matos et al described the clinical significance of this 
interaction in two patients who had a 53 and 2,000-fold increase in 
the frequency of ventricular premature beats during the phenytoin-
induced decline of disopyramide serum concentrations. 
9 
Based on these studies, we instituted a prospective controlled 
study evaluating the interaction between disopyramide and phenytoin in 
ten healthy volunteers. A statistically significant difference in the 
mean area under the plasma concentration-time curve of disopyramide 
before and after phenytoin administration was demonstrated; thus 
1-4 
confirming the sporadic findings of earlier studies. A number of 
mechanisms including changes in bioavailability, volume of distribu-
tion or elimination of disopyramide may explain the difference in the 
area under the plasma concentration time curve. 
When initially designing this study, we had hoped to measure both 
serum and urine disopyramide and MND concentrations. The assays 
necessary for these measurements however, were not available. Thus, 
there are no data on the extent of absorption of disopyramide. 
Interestingly, the time to maximum plasma concentration decreased 
after phenytoin administration, yet the maximum plasma concentration 
remained unchanged. Although absorption is incomplete at the time of 
the maximum plasma concentration, the lack of difference between the 
maximum plasma concentration before and after phenytoin administration 
suggests that there was no change in the extent of absorption of the 
disopyramide dose. However, because absorption may change after the 
maximum plasma concentration, the extent of absorption may not have 
remained constant. An increase in the pH of the gastrointestinal 
tract would increase the water solubility of a weak base such as 
disopyramide, and potentially explain the decreased time to maximum 
plasma concentration after phenytoin administration. A decrease in 
gastric motility may also hasten the time to maximum plasma concentra-
17 18 
tion. These effects have been reported with phenytoin therapy. ' 
10 
The effect of phenytoin on the disposition of other drugs usually 
is due to either a change in the protein binding or metabolism of the 
drug combined with phenytoin, and is not usually secondary to a change 
14 19 18 in absorption. ' However, Fine et al did demonstrate that 
phenytoin decreased the absorption of furosemide; unfortunately, the 
mechanism of this interaction was not determined. Other drugs which 
are reported to decrease the serum concentrations of disopyramide are 
2 
rifampin and phenobarbital. These interactions are secondary to 
enzyme induction with increased metabolism of disopyramide. 
Because we could not calculate the bioavailability of disopyra-
mide from the current study, we utilized previous data published on 
the bioavailability of disopyramide in calculating the apparent volume 
of distribution. The reported fraction of the dose of disopyramide 
absorbed ranges from 0.53 to 0.93, with 0.85 the most consistently 
8 12 
reported value. ' Therefore, we assumed the fraction of the disopyra^  
mide dose absorbed to be 0.85 in the current study. Because the 
protein binding of disopyramide is variable, pharmacokinetic fitting 
of disopyramide to a simple one compartment model without accounting 
for alterations in binding may result in an erroneous estimation of 
the apparent volume of distribution, elimination half-life and clear-
ance. However, our calculated apparent volume of distribution of 1 
L/kg is consistent with others.6 
Protein binding of disopyramide has been reported to range from 
30 to 80 percent,6,7'9 while more than 90 percent of phenytoin is 
protein bound. Although a number of drug interactions with phenytoin 
are due to an alteration in protein binding of the combined drug, drug 
interactions secondary to protein binding usually are not considered 
11 
20 significant unless both drugs are highly protein bound. Although we 
did not measure the protein binding of disopyramide in this study, we 
would not expect the mechanism of the disopyramide and phenytoin 
interaction to be secondary to an alteration in protein binding. If, 
however, phenytoin does displace protein bound disopyramide, this 
would increase the free fraction of disopyramide available for hepatic 
metabolism. Thus, an alteration in -protein binding could potentially 
account for the decrease in disopyramide and increase in MND serum 
concentrations demonstrated when phenytoin is added to disopyramide 
therapy. Phenytoin has been reported to increase alphas-acid glyco-
21 
protein serum concentrations which is the major binding site of 
disopyramide. The significance of this alteration in alphas-acid 
glycoprotein and its effect on the interaction between disopyramide 
and phenytoin is unknown. However, if phenytoin increases alphas-acid 
glycoprotein concentrations, this would increase the substrate avail-
able for disopyramide protein binding. An increase in the protein 
binding of disopyramide might result in a change in the volume of 
distribution and decrease clearance, which is inconsistent with our 
results. If phenytoin does displace protein bound disopyramide which 
would increase the free fraction of disopyramide, and phenytoin 
increases the alphas~acid glycoprotein concentrations which would 
increase the substrate available for disopyramide binding, perhaps 
these two factors offset one another and no change in disopyramide 
protein binding occurs. The elimination of our total drug concentra-
tion followed first order kinetics, which provides evidence that 
disopyramide protein binding did not change significantly. 
12 
Evaluation of the elimination rate constant, half-life and 
clearance of disopyramide before and after phenytoin, showed a statis-
tically significant difference in these parameters. These findings 
are consistent with the postulate that phenytoin increases the metabo-
lism of disopyramide, thereby shortening the half-life, increasing the 
clearance, lowering the area under the plasma concentration-time curve 
of disopyramide and resulting in increased serum concentrations of 
MND. The subjective data of increased anticholinergic adverse effects 
associated with disopyramide, after phenytoin administration, are also 
consistent with this postulate, because MND has 20 times the anticholi-
nergic activity of disopyramide.^ 
The change in half-life of disopyramide before and after pheny-
toin needs to be interpreted cautiously, because in most subjects data 
were available for calculation of only two disopyramide half-lives. 
Data on four or more half-lives would have been preferable in evaluat-
ing this change, but due to the kinetics of disopyramide and the 
assays available to measure disopyramide serum concentrations, such 
data were unobtainable. Nevertheless, if the variance is small as it 
was in our study, two half-lives may be quite accurate. 
Data points less than the sensitivity of the Emit® assay were 
reported by Searle Laboratories. Visual inspection of the graph 
showed these points in close line with the elimination phase of the 
curve. We did not use these data points in the calculations because 
the coefficient of variation of points less than the sensitivity of 
the assay could not be predicted. If we had used these data points, 
data for each subject would have been available to calculate at least 
three half-lives of disopyramide, thereby providing further support 
13 
for the change in half-lives observed before and after phenytoin 
therapy. Our calculated half-life of 8.2 hr, elimination rate con-
stant of 0.086 hr * and clearance of 111 ml/min of disopyramide before 
phenytoin administration are consistent with reports of others.6'7 
Based on the data from this study and previous work by Aitio et 
2 
al, we believe the interaction between disopyramide and phenytoin is 
due to an increase in hepatic metabolism by phenytoin which lowers the 
serum concentrations of disopyramide. Although our data do not 
provide a definitive mechanism of the interaction between disopyramide 
and phenytoin, they do clearly demonstrate a statistically significant 
difference in disopyramide concentrations before and after phenytoin 
administration. 
Because MND has 25 percent of the antiarrhythmic activity of 
disopyramide and a 20-fold increase in the anticholinergic activity of 
disopyramide, patients taking both disopyramide and phenytoin may 
experience a decreased therapeutic effect and an increased incidence 
of adverse drug reactions associated with disopyramide. 

15 
Figure 1. Serum disopyramide concentrations versus time 
SE 
• mean ± mean disopyramide serum concentration before 
phenytoin 
SE 
o mean ± mean disopyramide serum concentration after 
phenytoin 
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Figure 1. Serum disopyramide concentrations versus time 
* 
• 
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Table 1. Individual serum disopyramide concentrations before and 
after phenytoin administration 
Subject Number 
4 5 6 7 8 10 
Hours 
Pre-Phenytoin Disopyramide Concentrations 
(mcg/ml) 
0.00 0.0 0.0 0.0 0.0 0.0 . 0.0 0.0 0.0 0.0 0.0 
0.25 0.1 0.0 0.4 0.1 0.9 0.0 0.2 0.0 0.2 0.1 
0.50 1.8 0.4 2.2 1.0 2.3, 1.4 1.5 0.6 4.8a 1.3 
0.75 1.8 2.0 2.9 2.0 3.1 2.0 2.3 2.1 2.3 2.5 
1.00 2.3 3.1 3.0 2.6 3.2 2.4 2.6 2.7 2.4 2.6 
2.00 2.5 3.1 3.5 2.8 3.1 2.5 2.7 3.8 2.9 3.1 
3.00 2.0 2.9 2.5 2.7 3.0 2.4 2.4 3.5 2.5 2.3 
6.00 1.7 2.1 1.9 2.1 1.4 1.8 2.2b 2.6 1.7b 6. 3 a 
8.00 1.5 2.0 1.6 1.9 1.8 ' 1.4 1.8 2.3 1.7b 1.9 
12.00 1.0 1.3 0.9 1.4 1.6 1.1 1.2b 1.6 1.0 1.3 
24.00 0.4 0.5 0.4 0.5 0.6 lost 0.4 0.6 0.3 0.6 
Hours 
Post-Phenytoin Disopyramide Concentrations 
(mcg/ml) 
0.00 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
0.25 0.1 0.3 0.1 0.3 0.0 0.8 1.3 0.0 0.4 0.0 
0.50 1.0 2.2 1.0 2.4 2.1 2.5 1.2 1.4 1.6 2.1 
0.75 1.4 3. 1 2.2 3.0 3.4 2.9 1.2 3.1 2.1 2.8 
1.00 1.6 2.9 2.9 3.2 3.2 2.5 1.2 2.9 2.1 2.4 
2.00 2.8 2.6 1.8 2.3 2.5 1.9 2.0 2.5 1.9 2.5 
3.00 1.7 2.3 2.3 2.0 2.5 1.8 1.7 2.1 1.6 2.4 
6.00 1.0 1.4 1.2 1.1 1.7 1.0 1.1 1.6 1.1 1.3 
8.00 0.7 0.9 0.8 0.8 1.3 0.7 0.7 1.1 0.6 0.9 
12.00 0.4 0.4 0.4 0.4 0.7 0.4 0.3 0.6 0.3 0.5 
24.00 0.1 0. 1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 
a 22 Determined as outliers 
Assayed by gas chromatography 
19 
Table 2. Individual serum phenytoin concentrations 
Subject No. 
Phenytoin concentration 
(mcg/ml) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
22 
10 
10 
08 
07 
14 
25 
15 
08 
08 
20 
Table 3. Area under the plasma concentration-time curve (AUC) of 
disopyramide before and after phenytoin administration 
Pre-phenytoin AUC Post-phenytoin AUC 
Subject No. (mcg-hr/ml) (mcg-hr/ml) 
1 33.0 15.2 
2 42.5 20.4 
3 31.2 16.9 
4 42.2 18.1 
5 46.5 25.6 
6 33.4 16.6 
7 35.6 14.6 
8 50.1 22.7 
9 32.2 14.3 
10 44.4 20.3 
Mean 39.1 18.5 
SF mean 0.13 0.18 
p value < 0.0001 
21 
Table 4. Half-life (t^ s) of disopyramide before and after 
phenytoin administration 
Pre-phenytoin th Post-phenytoin t% 
Subject No. (hr) (hr) 
1 9.0 3.9 
2 8.3 3.9 
3 6.1 3.3 
4 8.6 3.8 
5 9.7 4.9 
6 7.9 ' 3.7 
7 6.9 4.0 
8 8.3 4.9 
9 7.1 3.8 
10 10.5 4.0 
Mean 8.2 4.0 
^mean 0.42 0.16 
p value < 0.0001 
22 
Table 5. Apparent volume of distribution (Vd) of disopyramide before 
and after phenytoin administration 
Pre-phenytoin Vd Post-phenytoin Vd 
Subject No. (L/kg) (L/kg) 
1 1.2 1.2 
2 0.8 ' 0.8 
3 1.0 1.0 
4 0.8 0.8 
5 0.8 0.9 
6 1.2 ' 1.2 
7 1.0 1.3 
8 0.7 0.9 
9 1.1 1.4 
10 1.1 0.9 
Mean 1.0 1.0 
9F mean 0 . 0 . 
p value 0. 
23 
Table 6. Clearance (CI) of disopyramide before and after 
phenytoin administration 
Pre-phenytoin CI Post-phenytoin CI 
Subject No. (ml/min) (ml/min) 
1 128 280 
2 100 ' 209 
3 136 251 
4 101 235 
5 091 166 
6 127 ' 256 
7 119 290 
8 084 187 
9 132 297 
10 096 209 
Mean 111 238 
SEmean 06.0 14.1 
p value < 0.0001 
24 
Table 7. Elimination rate constant (ke^) of disopyramide before and 
after phenytoin administration 
Pre-phenytoin Post-phenytoin k ei 
Subject No. (hr-1) (hr~l) 
1 0.077 0.177 
2 0.083 0.176 
3 0.113 0.212 
4 0.080 0.181 
5 0.072 0.142 
6 0.088 0.189 
7 0.101 0.175 
8 0.083 0.141 
9 0.097 0.182 
10 0.066 0.174 
Mean 0.086 0.175 
SEmean 0.004 0.021 
p value <0.0001 
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Table 8. Maximum plasma concentration (Cp max) of disopyramide 
before and after phenytoin administration 
Pre-phenytoin Cp max Post-phenytoin Cp max 
Subject No. (mcg/ml) (mcg/ml) 
1 2.5 2.8 
2 3.1 ' 3.1 
3 3.5 3.9 
4 2.8 3.2 
5 3.2 3.4 
6 2.5 ' 2.9 
7 2.7 2.0 
8 3.8 3.1 
9 2.9 2.1 
10 3.1 2.8 
Mean 3.0 2.9 
SEmean 0.13 0.18 
p value 0. 
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Table 9. The time to maximum plasma concentration (T max) of 
disopyramide before and after phenytoin administration 
Pre-phenytoin T max Post-phenytoin T max 
Subject No. (hr) 4 (hr) 
1 2.00 2.00 
2 1.00 0.75 
3 2.00 1.00 
4 2.00 1.00 
5 1.00 0.75 
6 2.00 0.75 
7 2.00 2.00 
8 2.00 0.75 
9 2.00 0.75 
10 2.00 0.75 
Mean 1.80 1.10 
SF mean 0.13 0.1 
p value < 0.00 
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Table 10. Comparison of the mean area under the plasma concentration-
time curve (AUC) and half-life (t^) of disopyramide (DIS) 
including and excluding data points less than 0.5 mcg/ml 
Mean AUC of DIS 
(data pt. >0.5) 
Pre-phenytoin Post-phenytoin p value 
(mcg-hr/ml) (mcg-hr/ml) 
39.1 18.5 < 0.0001 
Mean AUC of DIS 
(data pt. <0.5) 39.9 18.6 < 0.0001 
(hr) (hr) 
Mean th of DIS 
(data pt. >0.5) 8.2 4.0 < 0.0001 
Mean th of DIS 
(data pt. <0.5) 8.5 4.1 < 0.0001 
* 
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CONSENT FORM 
You are invited to participate in a study to evaluate the effect 
of phenytoin on the elimination from the body of another drug, disopy-
ramide. Both of these drugs are used in the treatment of abnormal 
heart rhythms. 
The study will take two weeks to complete. On the first day, you 
will take by mouth 300 mg of disopyramide. You will then have 5 ml 
(one teaspoonful) of blood drawn from'your vein 0, 0.25, 0.5, 0.75, 1, 
2, 3, 6, 8, 12 and 24 hours after the dose. You will be given 300 mg 
of phenytoin for two weeks to be taken by you at home. We will then 
repeat the study by giving you another 300 mg dose of disopyramide and 
draw the same amount of blood at 0, 0..25, 0.5, 0.75, 1, 2, 3, 6, 8, 12 
and 24 hours after the dose. You will refrain from excessive exercise 
for 24 hours after taking the disopyramide. In addition we will draw 
an additional 5 ml of blood to measure the amount of phenytoin in your 
body. 
The benefits to you from participating in this study include a 
free physical exam, chest x-ray, EKG and laboratory tests to determine 
that you are healthy prior to the study. In addition you will receive 
$75.00 for your time spent getting the blood drawn. 
The risks of this study include pain from the venipuncture and 
side effects from the drugs such as dry mouth, blurred vision, and 
rarely, urinary retention. 
All records will remain confidential. Only the investigators 
will know the names of the volunteers choosing to participate. 
You may ask questions at any time regarding this study by contact-
ing Dr. Jean Nappi, 581-8510 or Dr. Keith Tolman, 581-2121. 
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Medical treatment or compensation for physical injury: In the 
event you sustain physical injury resulting from the research project 
in which you are participating, the University of Utah will provide 
you, without charge, emergency and temporary medical treatment not 
otherwise covered by insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting 
in the course and scope of their employment, the University may be 
liable, subject to limitations prescribed by law, for additional 
* 
medical costs and other damages you sustain. If you believe that you 
have suffered a physical injury as a result of participation in this 
research program, please contact the Office of Research Administra-
tion, phone number 581-6903. 
Your participation is voluntary, and you may withdraw from the 
study at any time. Refusal to participate will involve no penalty or 
loss of benefits to which you are otherwise entitled. 
Study Participant Date 
Investigator Date 

DISOPYRAMIDE-PHENYTOIN DRUG INTERACTION STUDY 
August 18, 1983 - September 1, 1983 
Janice Rando, Pharm.D. Candidate 
Subject No. 
Phenytoin Monitoring Parameters 
* 
8/22 8/26 8/29 
Nystagmus 
Skin rash 
Blurred vision 
Double vision 
Mental confusion 
Slurred speech 
Staggering walk 
Constipation 
Nausea/vomiting 
Disopyramide Monitoring Parameters 
8/17 8/18 8/31 
Dry Mouth 
Blurred vision 
Urinary hesitancy 
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